Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction

Felicita Andreotti; Filippo Crea; Giampaolo Niccoli; Francesca Marzo; Silvia Cecchetti; Eleonora Santucci; Domenico D'Amario; Nicola Cosentino

doi:10.1111/j.1365-2362.2011.02528.x

Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction

Felicita Andreotti, Filippo Crea, Giampaolo Niccoli, Francesca Marzo, Silvia Cecchetti, Eleonora Santucci, Domenico D'Amario, Nicola Cosentino

Risultato della ricerca: Contributo in rivista › Articolo in rivista

14 Citazioni (Scopus)

Abstract

In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).

Lingua originale	English
pagine (da-a)	1210-1219
Numero di pagine	10
Rivista	European Journal of Clinical Investigation
Volume	41
DOI	https://doi.org/10.1111/j.1365-2362.2011.02528.x
Stato di pubblicazione	Pubblicato - 2011

Keywords

Aged
Biological Markers
Coronary Angiography
Electrocardiography
Erythropoietin
Female
Humans
Male
Middle Aged
Myocardial Infarction
No-Reflow Phenomenon
Regression Analysis

Accesso al documento

10.1111/j.1365-2362.2011.02528.x

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{c490159cff3944d297283015cc40e687,

title = "Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction",

abstract = "In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).",

keywords = "Aged, Biological Markers, Coronary Angiography, Electrocardiography, Erythropoietin, Female, Humans, Male, Middle Aged, Myocardial Infarction, No-Reflow Phenomenon, Regression Analysis, Aged, Biological Markers, Coronary Angiography, Electrocardiography, Erythropoietin, Female, Humans, Male, Middle Aged, Myocardial Infarction, No-Reflow Phenomenon, Regression Analysis",

author = "Felicita Andreotti and Filippo Crea and Giampaolo Niccoli and Francesca Marzo and Silvia Cecchetti and Eleonora Santucci and Domenico D'Amario and Nicola Cosentino",

year = "2011",

doi = "10.1111/j.1365-2362.2011.02528.x",

language = "English",

volume = "41",

pages = "1210--1219",

journal = "European Journal of Clinical Investigation",

issn = "0014-2972",

publisher = "Blackwell Science Limited:PO Box 88, Oxford OX2 0NE United Kingdom:011 44 1865 776868, 011 44 1865 206038, EMAIL: journals.cs@blacksci.co.uk, INTERNET: http://www.blackwell-science.com, Fax: 011 44 1865 721205",

}

TY - JOUR

T1 - Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction

AU - Andreotti, Felicita

AU - Crea, Filippo

AU - Niccoli, Giampaolo

AU - Marzo, Francesca

AU - Cecchetti, Silvia

AU - Santucci, Eleonora

AU - D'Amario, Domenico

AU - Cosentino, Nicola

PY - 2011

Y1 - 2011

N2 - In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).

AB - In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).

KW - Aged

KW - Biological Markers

KW - Coronary Angiography

KW - Electrocardiography

KW - Erythropoietin

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - No-Reflow Phenomenon

KW - Regression Analysis

KW - Aged

KW - Biological Markers

KW - Coronary Angiography

KW - Electrocardiography

KW - Erythropoietin

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - No-Reflow Phenomenon

KW - Regression Analysis

UR - http://hdl.handle.net/10807/4260

U2 - 10.1111/j.1365-2362.2011.02528.x

DO - 10.1111/j.1365-2362.2011.02528.x

M3 - Article

VL - 41

SP - 1210

EP - 1219

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

ER -

Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo